ROIV Maintained by Jefferies -- Price Target Raised to $52.00

On September 8, 2026, Roivant Sciences ROIV received a "Buy" rating from Jefferies, with the price target raised from $42.00 to $52.00. This adjustment reflects a significant increase of 23.81% in the price target, indicating continued positive sentiment regarding the company's performance. GF Value™ verdict: $7.25 vs Current Price $41.74 = 475.7% overvalued GF Score™: 51/100, indicating average performance across various metrics Insider activity: 3 insiders sold shares totaling approximately $247.5 million in the last three months What's Behind the Analyst Rating? The recent upgrade in Roivant Sciences' price target from Jefferies signifies a strong belief in the company's growth potential and market position. The healthcare sector, particularly biotechnology, has been under scrutiny for its volatility, yet Roivant has managed to maintain a favorable outlook among analysts. The company is currently valued at approximately $30.15 billion, reflecting its commercial-stage biopharmaceutical status and the promising pipeline of drug candidates, including VTAMA, which is aimed at treating plaque psoriasis. Roivant Sciences Ltd is dedicated to enhancing healthcare delivery through its biopharmaceutical initiatives and incubating complementary health technology startups. The company has a diverse portfolio of drug candidates in various development stages, which adds to its growth prospects and justifies the positive analyst sentiment. Is ROIV Overvalued or Undervalued? According to the GF Value™ metric, Roivant Sciences is currently significantly overvalued, with a GF Value™ of $7.25 compared to its current price of $41.74. This represents a staggering 475.7% overvaluation, indicating that investors may be paying a premium for the stock that is not supported by its intrinsic value. The price-to-sales (P/S) ratio stands at an astronomical 211.25, far exceeding its historical median, which raises concerns about the sustainability of its current valuation. Given that the company is unprofitable with a TTM EPS of -0.53, traditional earnings-based valuation metrics like P/E are not applicable in this scenario. For further details, you can view the GF Value™. What Does ROIV's GF Score™ Tell Us? The GF Score™ is a comprehensive measure that evaluates a company's financial strength, profitability, growth, valuation, and momentum. Roivant Sciences has a GF Score™ of 51 out of 100, indicating an average performance across these dimensions. The strongest sub-rank is in growth, while the weakest is in profitability, reflecting the challenges the company faces in generating consistent earnings. Metric Rating GF Score™ 51 Financial Strength 7/10 Growth 6/10 Valuation 1/10 Momentum 3/10 While Roivant demonstrates solid financial strength and growth potential, its profitability remains a significant concern, as evidenced by its low profitability rank. This indicates that while the company may have a promising future, it currently struggles to convert revenues into profits. For more insights, visit the ROIV stock page. What Are Gurus and Insiders Doing with ROIV? Currently, 8 gurus hold shares of Roivant Sciences, with 4 adding to their positions and 3 trimming their holdings in recent quarters. This indicates a mixed sentiment among institutional investors, which can be a crucial signal for retail investors. Additionally, insider activity shows significant selling, with insiders offloading shares worth approximately $247.5 million in the last three months, raising concerns about their confidence in the company's future performance. What This Means for Investors Given the significant overvaluation indicated by the GF Value™ and the mixed signals from guru ownership and insider activity, investors should approach Roivant Sciences with caution. While the company has strong growth potential, the current valuation metrics suggest that it may not be a prudent investment at this time. For a deeper analysis, check out the ROIV stock page. Frequently Asked Questions What is ROIV's GF Score™? ROIV's GF Score™ is 51 out of 100, indicating average performance across various financial metrics. Is ROIV overvalued or undervalued? ROIV is significantly overvalued, with a GF Value™ of $7.25 compared to its current price of $41.74, indicating a 475.7% overvaluation. What do analysts recommend for ROIV? Analysts currently maintain a "Buy" rating for ROIV, with a recent price target increase reflecting positive sentiment about the company's growth prospects.